Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM)  is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood.

On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company’s Alpha-1 Antitrypsin Deficiency program received a favorable regulatory update before the change. The latest regulatory action was Bernstein’s main stock catalyst for 2026. The company also noted several impending benchmarks, such as the anticipated release of revised AATD data in the first quarter of 2026, which are still important events to keep an eye on through the end of the year.

Separately, UBS began covering Beam Therapeutics Inc. (NASDAQ:BEAM) on January 7, 2026, with a $28 price goal and a neutral rating. The launch was a component of a larger coverage action that targeted 22 small- to mid-cap biotechnology firms. As reported by UBS, biotechnology fundamentals are starting to improve after a challenging time, and investor confidence is expected to rebound, setting the industry up for further success in 2026.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm focused on developing a new class of precision genetic drugs.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026. 

Disclosure: None. This article is originally published at Insider Monkey.